Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Pens Drug Repositioning Pact with Abbott

NEW YORK (GenomeWeb News) - Gene Logic said today that it has signed a drug-repositioning agreement with Abbott that covers multiple clinical drug candidates that have passed Phase I human clinical trials.
Gene Logic said it stands to receive milestone payments for each new drug candidate that Abbott reenters into clinical development, as well as royalties for drug candidates that make it to market.
Gene Logic also will have the option to an exclusive license to any new drug candidate that Abbott chooses not to pursue. In such a case, Gene Logic would pay royalties to Abbott.
A Gene Logic spokeswoman said this open-ended agreement is the first such agreement it has entered with Abbott. Under its drug repositioning program, Gene Logic has partnerships with Pfizer, Roche, and other pharmaceutical companies.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.